By Lucia Bird Ruiz Benitez de Lugo, Mouhamadou Kane, Jason Eligh and Lyes Tagziria

Across Africa, the GI-TOC has documented the proliferation of synthetic drugs, the resulting transformation of drugs markets and the escalation of drug-related harm. The nature of synthetic drug markets – with their low barriers to entry and flexible supply chains – makes them attractive to criminal actors and difficult to respond to. The response in Africa is further hampered by a dearth of evidence regarding the scope and scale of the synthetic drug market. This report explores how synthetic drug markets respond to programming seeking to disrupt them. Tramadol is used as a lens through which to consider existing response frameworks to synthetic drugs in the ECOWAS region and more broadly.

ENACT Africa, 2024.